| Trial ID: | L0772 |
| Source ID: | NCT03801577
|
| Associated Drug: |
Hepaxa
|
| Title: |
Hepaxa Management of Non-Alcoholic Fatty Liver Disease (NAFLD): A Real-world Pilot Study Observing Effects of Nutritional Management With Hepaxa in Subjects With Liver Steatosis
|
| Acronym: |
--
|
| Status: |
Not recruiting
|
| Study Results: |
No Results Available
|
| Results: |
--
|
| Conditions: |
Non-Alcoholic Fatty Liver Disease;Non Alcoholic Fatty Liver;NASH - Nonalcoholic Steatohepatitis
|
| Interventions: |
Dietary Supplement: Hepaxa
|
| Outcome Measures: |
The change in liver fat content (hepatic steatosis) from baseline to end of studyChange in liver function test: aspartate aminotransferase (AST) from baseline (IU/L) to end of study;Change in the liver function test: alanine aminotransferase (ALT) from baseline (IU/L) to end of study;Change in the liver function test: gamma glutamyltransferase (GGT) from baseline (IU/L) to end of study;Change in Level of plasma triglycerides from baseline to end of study;Change in weight from baseline to end of study
|
| Sponsor/Collaborators: |
BASF AS
|
| Gender: |
All
|
| Age: |
18 Yearsnan
|
| Phases: |
Not applicable
|
| Enrollment: |
50
|
| Study Type: |
Interventional
|
| Study Designs: |
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
|
| Start Date: |
09/01/2019
|
| Completion Date: |
--
|
| Results First Posted: |
--
|
| Last Update Posted: |
12 December 2020
|
| Locations: |
United States
|
| URL: |
https://clinicaltrials.gov/show/NCT03801577
|
